Lexicon Pharmaceuticals, Inc.
LXRX
$0.3918
$0.02416.55%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Net Income | -21.30% | -10.40% | 2.73% | 1.52% | -12.52% |
| Total Depreciation and Amortization | -9.35% | -3.47% | -2.04% | -2.65% | 4.86% |
| Total Amortization of Deferred Charges | -23.43% | 1.55% | -16.34% | 0.00% | 126.37% |
| Total Other Non-Cash Items | 3,996.00% | -100.61% | 49.85% | 854.39% | -92.53% |
| Change in Net Operating Assets | 128.00% | 137.05% | -168.18% | -154.47% | 207.32% |
| Cash from Operations | -10.46% | 11.95% | -9.06% | -21.45% | -9.19% |
| Capital Expenditure | -22.80% | -- | -- | 100.00% | 40.29% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 545.42% | 89.05% | -312.39% | 232.25% | 47.30% |
| Cash from Investing | 533.90% | 88.82% | -312.39% | 231.97% | 47.29% |
| Total Debt Issued | -- | -- | -- | -200.00% | -100.00% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -100.00% | -98.86% | -- | -- | -- |
| Repurchase of Common Stock | -- | 100.00% | -- | 100.00% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | 33.33% | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 100.00% | -- | -- | -- |
| Cash from Financing | -6,442.86% | -100.01% | 23,938,400.00% | 99.52% | -100.11% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 98.25% | -182.23% | 5,387.69% | 101.66% | -206.40% |
